- Home
- UNCY vs FATE Comparison
UNCY vs FATE Comparison
Compare UNCY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNCY | FATE |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.3M | 125.6M |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UNCY | FATE |
|---|---|---|
| Price | $5.07 | $2.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $25.67 | $4.10 |
| AVG Volume (30 Days) | 832.9K | ★ 2.4M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | $675,000.00 | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $582.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.72 | $0.91 |
| 52 Week High | $8.74 | $3.23 |
Technical Indicators
Market Signals| Indicator | UNCY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 47.63 |
| Support Level | $4.81 | $1.01 |
| Resistance Level | $5.39 | $3.22 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 29.31 | 37.50 |
Price Performance
Historical ComparisonAbout UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.